替罗非班对糖尿病肾病患者血小板活性和肾功能的影响

目的:探讨血小板糖蛋白Ⅱb/Ⅲa受体拮抗药替罗非班对糖尿病肾病患者血小板活性和肾功能的影响。方法:20例健康体检者为对照组(CON组),33例糖尿病肾病患者随机分为替罗非班治疗组(TM组)和糖尿病肾病组(DN组),分别检测3组治疗前和治疗后1个月的血小板计数(PLT)、平均血小板体积(MPV)、血小板激活复合物-1(PAC-1)、糖化血红蛋白(HbAlc)、尿素氮(BUN)、血肌酐(Scr)、尿微量白蛋白(MAU),并分析3组间的相关性。结果:与CON组比较,DN组的MPV、PAC-1、HbAlc、BUN、Scr、MAU水平明显增高(P<0.05);与DN组比较,TM组的MPV、PAC-1、BUN、Scr、MAU水平明显降低(P<0.05)。结论:糖尿病肾病患者血小板活性增高,小剂量替罗非班治疗能够抑制血小板活化,改善糖尿病肾病患者的肾功能。

Effects of Tirofiban on the Platelet Activation and Renal Function of Patients with Diabetic Nephropathy

OBJECTIVE：To investigate the effects of glycoprotein Ⅱb/Ⅲa receptor blockers tirofiban on the platelet activation and renal function in patients with diabetic nephropathy.METHODS：20 healthy volunteers were included in control group（CON group）,33 patients with diabetic nephropathy were randomly divided into tirofiban treatment group（TM group）and diabetic nephropathy group（DN group）.The platelet（PLT）count,mean platelet volume（MPV）,platelet activation compound（PAC-1）,glycosylated hemoglobin（HbAlc）,microscale albuminuria（MAU）,blood urea nitrogen（BUN）and serum creatinine（Scr）levels were detected before treatment and 3 months after treatment,and correlation analysis was conducted among three groups.RESULTS：Compared with CON group,the levels of MPV,PAC-1,HbAlc,MAU,BUN and Scr increased significantly in DN group（P0.05）;compared with DN group,the levels of MPV,PAC-1,MAU,BUN and Scr significantly decreased in TM groups（P0.05）.CONCLUSION：The active indexes of platelet are increased in patients with diabetic nephropathy,small-dose of tirofiban can inhibit platelet activation and improve renal function in patients with diabetic nephropathy.